The healthcare research specialist unveiled its first set of quarterly figures for 2026.

ICON delivered a modest 1Q26 beat, with EPS of $2.50 and revenue of $2.03B, but growth was subdued and margins compressed.

“ICON maintained strong commercial momentum in quarter one, delivering net bookings of $2.9B, and a net book-to-bill of 1.42, ...

Icon Plc ICLR shares are crashing in Thursday’s premarket session as the company disclosed an update on its upcoming earnings report. The clinical research organisation disclosed an ongoing internal ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-conviction stock picks and new investing ...

ICON plc ICLR is well-poised to grow in the upcoming quarters, driven by its strategic additions. Leveraging AI and technology advancements, the company is optimizing clinical delivery and has seen ...

Drug and medical device maker ICON agrees to buy PRA Health Sciences in a cash-and-stock transaction valued at about $12 billion.

Icon (NASDAQ:ICLR) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...